nicvax
Vaccineexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT00218413)
Timeline
Indications
Mechanism of action
- nicotineImmunity, active
nicotine immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nicvax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01375933 | Phase 3 | May 1, 2011 | Nabi Biopharmaceuticals |
| NCT01318668 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2011 | Maastricht University |
| NCT01178346 | Phase 3 | Jul 1, 2010 | GlaxoSmithKline, Nabi Biopharmaceuticals |
| NCT01102114 | Phase 3 | Mar 1, 2010 | Nabi Biopharmaceuticals |
| NCT00836199 | Phase 3 | Oct 1, 2009 | Nabi Biopharmaceuticals, National Institute on Drug Abuse (NIDA) |
| NCT00995033 | Phase 2 | Oct 1, 2009 | Maastricht University, Nabi Biopharmaceuticals, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT00996034 | Phase 2 | Sep 1, 2009 | Nabi Biopharmaceuticals, National Institute on Drug Abuse (NIDA), Yale University |
| NCT00598325 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2008 | Nabi Biopharmaceuticals |
| NCT00218413 | Phase 2 | Oct 1, 2004 | Nabi Biopharmaceuticals, National Institute on Drug Abuse (NIDA) |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nabi Biopharmaceuticals | For profit | 8 | 6 | 2 | 2004 |
| National Institute on Drug Abuse (NIDA) | Government | 3 | 0 | 2 | 2004 |
| Maastricht University | Academic/Hospital | 2 | 2 | 1 | 2009 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2010 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| ZonMw: The Netherlands Organisation for Health Research and Development | Academic/Hospital | 1 | 0 | 1 | 2009 |
6 organizations
Page 1 / 1